自膨胀镍钛支架与经皮腔内血管成形术治疗股腘动脉病变:SM-01试验3年数据
SM-01试验为日本单盲多中心随机对照研究,比较自膨胀镍钛支架与PTA(必要时置入支架)治疗股腘动脉病变。共105例患者入组,意向性分析纳入支架组51例、PTA组52例。3年随访显示支架组一期通畅率更高(73% vs 51%,p=0.033),但临床驱动的靶血管/靶病变血运重建率两组无显著差异。
要点
- 支架组3年一期通畅率显著高于PTA组(73% vs 51%,p=0.033)。
- 支架组技术成功率更高(100% vs 48%,p<0.001),血管夹层更少(4% vs 31%,p<0.001)。
- 两组临床驱动靶血管/靶病变血运重建率无显著差异。
核心结论
- 在股腘动脉病变中,自膨胀镍钛支架3年一期通畅率高于PTA,但临床驱动血运重建需求两组相似。
研究设计与样本
- SM-01研究为日本单盲、多中心、随机对照试验(NCT01183117),纳入105例连续患者。
- 剔除方案违背后,支架组51例(平均年龄74±8岁,男36例)和PTA组52例(平均年龄73±8岁,男35例)纳入意向性分析。
- 随访至36个月,采用双功超声评估,以收缩期峰值流速比<2.5定义一期通畅。
主要发现
- 支架组技术成功率100%,PTA组48%(p<0.001)。
- 支架组血管夹层发生率4%,PTA组31%(p<0.001)。
- 支架组3年一期通畅率73%,PTA组51%(p=0.033)。
- 两组临床驱动靶血管血运重建(TVR)和靶病变血运重建(TLR)无显著差异。
关键数值与推荐
- 3年一期通畅率定义为双功超声收缩期峰值流速比<2.5。
- TVR和TLR采用Kaplan-Meier法估计。
临床怎么用
- 对于股腘动脉病变,自膨胀镍钛支架可提高3年影像学通畅率,但未显著减少临床驱动的再次血运重建。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the midterm outcomes of a trial comparing self-expanding nitinol stents to percutaneous transluminal angioplasty (PTA) with provisional stenting in the treatment of obstructive disease in the superficial femoral and popliteal arteries. MATERIALS AND METHODS: The SM-01 study ( ClinicalTrials.gov identifier NCT01183117), a single-blinded, multicenter, randomized controlled trial in Japan, enrolled 105 consecutive patients with de novo or postangioplasty restenotic femoropopliteal lesions; after removing protocol violations (1 from each group), 51 patients (mean age 74±8 years; 36 men) in the stent group and 52 patients (mean age 73±8 years; 35 men) in the PTA group were included in the intention-to-treat analysis. The groups were well-matched at baseline. Patients were followed to 36 months with duplex imaging. Three-year primary patency was assessed based on a duplex-derived peak systolic velocity ratio <2.5. Freedom from clinically-driven target vessel revascularization (TVR) and target lesions revascularization (TLR) were estimated using the Kaplan-Meier method. RESULTS: The technical success rate was higher (100% vs 48%, p<0.001) and the frequency of vascular dissection was lower (4% vs 31%, p<0.001) in the stent group. The S.M.A.R.T stent group had a higher 3-year primary patency rate (73% vs 51%, p=0.033). Freedom from clinically-driven TVR and TLR were not significantly different between the groups. CONCLUSION: The S.M.A.R.T. stent maintained a higher primary patency rate than PTA at 3 years in this randomized trial; the need for clinically-driven revascularization was similar for both therapies.
引用
- Iida O, Urasawa K, Komura Y, et al. Self-Expanding Nitinol Stent vs Percutaneous Transluminal Angioplasty in the Treatment of Femoropopliteal Lesions: 3-Year Data From the SM-01 Trial. J Endovasc Ther. 2019. PMID: 30702021. doi:10.1177/1526602819826591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。